An experimental oral drug called muvalaplin shows promise in reducing the cholesterol linked to heart disease in a study.
Drug manufacturers have increased their production, and some such as Novo Nordisk have asked the FDA to ban further production of compounded versions of their drugs. If that happens, Lavin says many ...